We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals
RXRX

267 hedge funds and large institutions have $1.74B invested in Recursion Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 112 increasing their positions, 52 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 52

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

2% less first-time investments, than exits

New positions opened: 44 | Existing positions closed: 45

1% less funds holding

Funds holding: 270 → 267 (-3)

8% less capital invested

Capital invested by funds: $1.89B → $1.74B (-$145M)

15.24% less ownership

Funds ownership: 109.46% → 94.22% (-15%)

42% less call options, than puts

Call options by funds: $11.4M | Put options by funds: $19.8M

Holders
267
Holders Change
-3
Holders Change %
-1.11%
% of All Funds
3.83%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
44
Increased
112
Reduced
52
Closed
45
Calls
$11.4M
Puts
$19.8M
Net Calls
-$8.4M
Net Calls Change
+$1.55M

Top Buyers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
+$33.2M
2
State Street
State Street
Massachusetts
+$29.5M
3
BlackRock
BlackRock
New York
+$24.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$19.5M
5
DM
Deerfield Management
New York
+$16.6M

Top Sellers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
-$21.8M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
-$9.68M
3
GCM
Ghisallo Capital Management
Massachusetts
-$8.25M
4
UBS Group
UBS Group
Switzerland
-$6.09M
5
PA
Perceptive Advisors
New York
-$5.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
First Trust Advisors
276
First Trust Advisors
Illinois
– -$711K -94,854 Closed
OAC
277
OMERS Administration Corp
Ontario, Canada
– -$701K -93,500 Closed
RJA
278
Raymond James & Associates
Florida
– -$562K -74,905 Closed
AGM
279
Alpine Global Management
New York
– -$475K -63,274 Closed
Thrivent Financial for Lutherans
280
Thrivent Financial for Lutherans
Minnesota
– -$465K -62,051 Closed
HCA
281
Harbour Capital Advisors
Virginia
– -$410K -55,025 Closed
DC
282
Diametric Capital
Massachusetts
– -$328K -43,771 Closed
BCM
283
Bayesian Capital Management
New York
– -$318K -42,400 Closed
SPA
284
Sherbrooke Park Advisers
New York
– -$251K -33,458 Closed
DnB Asset Management
285
DnB Asset Management
Norway
– -$248K -33,119 Closed
Man Group
286
Man Group
United Kingdom
– -$210K -27,971 Closed
VA
287
Vident Advisory
Georgia
– -$138K -18,363 Closed
AG
288
Algert Global
California
– -$129K -17,158 Closed
PCM
289
Prelude Capital Management
New York
– -$118K -15,794 Closed
GHAM
290
Gilman Hill Asset Management
Connecticut
– -$101K -13,500 Closed
FRM
291
Fox Run Management
Connecticut
– -$92.3K -12,311 Closed
AC
292
AXQ Capital
New Jersey
– -$82.2K -10,960 Closed
RWMG
293
Redwood Wealth Management Group
New Jersey
– -$18.8K -2,500 Closed
Pacer Advisors
294
Pacer Advisors
Pennsylvania
– -$17K -2,263 Closed
IUHSA
295
Itau Unibanco Holding S.A.
Brazil
– -$13.2K -1,756 Closed
FIA
296
FNY Investment Advisers
New York
– -$11K -1,511 Closed
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
297
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
– -$10.2K -1,366 Closed
SIM
298
Sandia Investment Management
Massachusetts
– -$7.5K -1,000 Closed
RAM
299
Riggs Asset Management
Pennsylvania
– -$2.96K -394 Closed
CA
300
Continuum Advisory
Idaho
– -$2.25K -300 Closed
9 10 11
12
13

RXRX Hedge Fund Activity: Q3 2024 in Review

267 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2024, worth a combined $1.74B — down 7.7% from $1.89B a quarter earlier.

Sellers outnumbered buyers: 45 funds closed out of RXRX and 44 opened new positions — a net loss of 1 holder — while 52 trimmed existing stakes and 112 added.

The largest buyer was ARK Investment Management, adding an estimated $33.2M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $21.8M sold.

  • 267 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2024, down from 270 in Q2 2024.
  • Funds reported $1.74B of Recursion Pharmaceuticals stock for Q3 2024, down 7.7% quarter-over-quarter.
  • 44 funds opened new Recursion Pharmaceuticals positions in Q3 2024 and 45 closed out, a net change of -1 holder.
  • The largest Recursion Pharmaceuticals buyer in Q3 2024 was ARK Investment Management, an estimated $33.2M added.
  • The largest Recursion Pharmaceuticals seller in Q3 2024 was Laurion Capital Management, an estimated $21.8M sold.

Based on aggregated 13F filings for Q3 2024.